Articles By Jack Cush, MD
Biologic Prescribing and Patient Education
Biologics are big. Their popularity is reflected in their growing use since being introduced in 1998. Biologics have been used by more than 3 million patients worldwide. In 2013, Enbrel, Remicade and Humira accounted for nearly $30 billion in worldwide sales. In the USA, it is estimated that we will spend $220 billion on biologics by 2017.
Read Article
A Rheumatologist's Guide to Bariatric Surgery
Obesity is epidemic in North America, affecting nearly 76 million adults. Obesity is not only a risk factor for rheumatoid arthritis and osteoarthritis, it clearly worsens pain and function in most musculoskeletal (MSK) conditions and has been shown to blunt DMARD and biologic resp
Read Article
Simple Referral Rule May Lead to Earlier Referral and Diagnosis of Axial Spondyloarthritis
Early referral and diagnosis remains a challenge for many who care for patients with musculoskeletal complaints. This is especially so in those with chronic low back pain (LBP) and the minority who will have ankylosing spondylitis or axial spondyloarthritis.
Read Article
CDC Updates Arthritis Numbers
The Centers for Disease Control and Prevention (CDC) routinely surveys the population prevalence of certain chronic disorders, including arthritis.
Read Article
RheumNow Anniversary Perspective
Dr. Jack Cush provides a perspective on the first year anniversary of RheumNow.com - a site dedicated to delivering the wisdom, art and science of Rheumatology.
Read Article
Biosimilar Switching Shows Favorable Interchangeability
Interchangeability is a major issue that will determine the success of biosimilars.
Read Article
Poor Outcomes for Dermato/Polymyositis Admitted to ICU
Idiopathic inflammatory myopathies (IIMs) may be complicated with life-threatening conditions requiring intensive care unit (ICU) admission. The outcomes of such complications may be dire, but there are few series addressing the outcomes of those admitted to the ICU.
Read Article
Consensus Guideline on Drug Therapy After Osteoporotic Fractures
Silverman and a panel from the IOF Fracture Working Group reviewed the data and trials to develop guidelines for the use of osteoporosis medications after incident fractures or to treat delayed fracture healing.
Read Article
KOLs Predict: What Will the Next Year Bring?
A new subspecialty may emerge. New drugs will be approved (but it will be difficult for patients to get coverage for them). And an American team will win the World Series. All these and more: here are predictions for 2017 and beyond from rheumatologists across the country and around the world.
Read Article
Low Adherence to Biologics in Psoriasis Patients
Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.
Read Article
